Download the Protocol

ARA-290

ARA-290 is a small lab-made compound that helps the body protect and repair its own tissues. It is being studied for nerve pain and inflammation, as it can calm the immune system and support natural healing without changing blood cell levels like some related hormones do.

Description

• ARA-290 (Cibinetide) is an 11–amino acid peptide derived from the tissue-protective region of erythropoietin.
• Developed to provide anti-inflammatory and cytoprotective effects without increasing red blood cell count.
• Studied for neuropathic pain, inflammatory disorders, and ischemic tissue injury.

How It Works

• Binds to the innate repair receptor (IRR), a complex of EPOR and CD131 subunits.
• Triggers protective signaling that reduces inflammation, oxidative stress, and apoptosis.
• Does not stimulate the erythropoietic receptor responsible for red blood cell production.

Documented Effects

• Reduces neuropathic pain and improves small nerve fiber function in clinical studies.
• Decreases inflammatory cytokines (IL-6, TNF-α) and promotes cellular repair.
• Enhances healing and reduces ischemic injury in kidney, heart, and corneal models.
• Improves autonomic nerve activity and microvascular function in diabetic neuropathy.
• Exhibits anti-fatigue and tissue recovery effects in preclinical research.

Theoretical Effects

• May support mitochondrial stability and cellular regeneration post-injury.
• Potential to modulate immune tolerance and limit autoimmune inflammation.
• Possible systemic benefits on energy, cognition, and metabolic health are unconfirmed in humans.

Pharmacokinetics

• Half-life: approximately 2 hours after subcutaneous injection.
• Time to peak concentration: about 30–60 minutes post-injection.
• Steady-state: achieved within 2–3 days of consistent daily use.

Duration of Effects

• Therapeutic effects typically last 6–12 hours after each dose.
• Anti-inflammatory and pain-reducing benefits build gradually with regular use.
• Effects decline within 1–2 days after discontinuation.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 10 mg of ARA-290
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~21 days for best stability.

ARA-290 – Injectable Dosage Overview (First-Time Use)

Typical Starting Dose

• Injectable (investigational, evidence-based): ~2–4 mg subcutaneous (SC) once daily.
• Conservative entry point: start at ~2 mg SC to evaluate tolerance.

Common Therapeutic Range

• Injectable reports: 2–4 mg SC daily → up to 8 mg/day in clinical protocols.
• Primarily used in trials for neuropathic pain and inflammatory repair processes.

Maximum Daily Dose

• Clinical ceiling: ~8 mg/day SC.
• Doses above this range lack safety or efficacy validation.

Standard Cycle Length

• Therapeutic cycles typically 4–6 weeks daily use.
• For chronic conditions: repeated cycles (4 weeks on, 2–4 weeks off) have been used in studies.

Clinical Notes

• Administer subcutaneously in the abdomen or thigh using sterile technique.
• No tapering required; effects diminish naturally within days after stopping.
• May be combined cautiously with anti-inflammatory or regenerative peptides if supervised.
• Stable for about 21 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Start at lower end of range (~2 mg) and increase only if well tolerated.
• Potential effects: pain relief, improved energy, mild transient fatigue or headache.
• Maintain sterile injection practices at all times.
• Ensure proper cold storage after reconstitution (2–8°C).
• Long-term human data remain limited; intended for research use only.